Tyra Biosciences Inc. (TYRA)
NASDAQ: TYRA
· Real-Time Price · USD
10.48
0.18 (1.75%)
At close: May 01, 2025, 3:59 PM
9.68
-7.63%
Pre-market: May 02, 2025, 04:12 AM EDT
1.75% (1D)
| Bid | 7.4 |
| Market Cap | 531.86M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -86.48M |
| EPS (ttm) | -1.51 |
| PE Ratio (ttm) | -6.94 |
| Forward PE | -4.56 |
| Analyst | Buy |
| Ask | 11 |
| Volume | 273,419 |
| Avg. Volume (20D) | 317,275 |
| Open | 10.27 |
| Previous Close | 10.30 |
| Day's Range | 10.13 - 10.56 |
| 52-Week Range | 6.42 - 29.60 |
| Beta | 1.19 |
About TYRA
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondro...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 15, 2021
Employees 60
Stock Exchange NASDAQ
Ticker Symbol TYRA
Website https://www.tyra.bio
Analyst Forecast
According to 6 analyst ratings, the average rating for TYRA stock is "Buy." The 12-month stock price forecast is $30.5, which is an increase of 191.03% from the latest price.
Stock Forecasts6 months ago
-23.35%
Tyra Biosciences shares are trading lower. The com...
Unlock content with
Pro Subscription
